Cardiff Oncology
(NASDAQ) CRDF
Cardiff Oncology Financials at a Glance
Market Cap
$90.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$525.00K
Net Income (TTM)
-$44.76M
EPS (TTM)
-$0.67
P/E Ratio
-2.00
Dividend
$0.00
Beta (Volatility)
1.74 (High)
Dividend
$0.00
Beta (Volatility)
1.74 (High)
Price
$1.33
Volume
802,515.674
Open
$1.32
Price
$1.33
Volume
802,515.674
Open
$1.32
Previous Close
$1.33
Daily Range
$1.24 - $1.34
52-Week Range
$1.16 - $4.56
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
1.74 (High)
Price
$1.33
Volume
802,515.674
Open
$1.32
Previous Close
$1.33
Daily Range
$1.24 - $1.34
52-Week Range
$1.16 - $4.56
Estimated Earnings Date
Aug 4, 2026
CRDF News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cardiff Oncology
Industry
Biotechnology
Sector
Health CareEmployees
31
CEO
Mani Mohindru, PhD
Website
www.cardiffoncology.comHeadquarters
San Diego, CA 92121, US
CRDF Financials
Key Financial Metrics (TTM)
Gross Margin
-2105.71%
Operating Margin
-9033.90%
Net Income Margin
-8526.10%
Return on Equity
-95.50%
Return on Capital
-105.93%
Return on Assets
-91.03%
Earnings Yield
-50.00%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$90.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
68.37M
Volume
802.52K
Avg. Volume
1.23M
Financials (TTM)
Gross Profit
-$11.06M
Operating Income
-$47.43M
EBITDA
-$43.73M
Operating Cash Flow
-$37.42M
Capital Expenditure
-$44.00K
Free Cash Flow
-$37.46M
Cash & ST Invst.
$46.06M
Total Debt
$646.00K
Cardiff Oncology Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$41.00K
-62.4%
Gross Profit
$41.00K
-62.4%
Gross Margin
100.00%
N/A
Market Cap
$90.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$2.93M
N/A
Employees
31
N/A
Net Income
-$12.35M
+8.1%
EBITDA
-$12.12M
+8.2%
Quarterly Fundamentals
Total Cash
$46.06M
-42.3%
Total Debt
$646.00K
-52.4%
Accounts Receivable
$191.00K
-52.8%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$646.00K
-9.8%
Return on Assets
-91.03%
N/A
Return on Invested Capital
-1.37%
N/A
Free Cash Flow
-$12.29M
+4.0%
Operating Cash Flow
-$12.29M
+4.0%